Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: J Urol. 2014 Mar 25;192(3):743–748. doi: 10.1016/j.juro.2014.03.091

Figure 3.

Figure 3

Adjusted risk of secondary cancer therapy at 5 years by quality of care of healthcare system for patients with low-risk (panel A) and high-risk prostate cancer (panel B). Patients were stratified by type of primary treatment received (prostatectomy, radiotherapy without or with concurrent androgen-deprivation therapy [ADT]).